<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Chlorpromazine versus piperacetazine for schizophrenia - Eslami Shahrbabaki, M - 2018 | Cochrane Library</title> <meta content="Chlorpromazine versus piperacetazine for schizophrenia - Eslami Shahrbabaki, M - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011709.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Chlorpromazine versus piperacetazine for schizophrenia - Eslami Shahrbabaki, M - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011709.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011709.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Chlorpromazine versus piperacetazine for schizophrenia" name="citation_title"/> <meta content="Mahin Eslami Shahrbabaki" name="citation_author"/> <meta content="Kerman University of Medical Sciences, Afzalipour School of Medicine" name="citation_author_institution"/> <meta content="Reza Dehnavieh" name="citation_author"/> <meta content="Kerman University of Medical Sciences" name="citation_author_institution"/> <meta content="Leila Vali" name="citation_author"/> <meta content="Kerman University of Medical Sciences" name="citation_author_institution"/> <meta content="Rahim Sharafkhani" name="citation_author"/> <meta content="Khoy University of Medical Sciences" name="citation_author_institution"/> <meta content="R_sharafkhani@yahoo.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD011709.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/10/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011709.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011709.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011709.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [adverse effects, *therapeutic use]; Chlorpromazine [adverse effects, *therapeutic use]; Phenothiazines [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011709.pub2&amp;doi=10.1002/14651858.CD011709.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="loVWuZlx";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011709\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011709\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011709.pub2",title:"Chlorpromazine versus piperacetazine for schizophrenia",firstPublishedDate:"Oct 31, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011709.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011709.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011709.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011709.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011709.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011709.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011709.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011709.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011709.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011709.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2282 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011709.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-sec-0176"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-sec-0106"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-sec-0159"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/table_n/CD011709StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/table_n/CD011709StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Chlorpromazine versus piperacetazine for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/information#CD011709-cr-0002">Mahin Eslami Shahrbabaki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/information#CD011709-cr-0003">Reza Dehnavieh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/information#CD011709-cr-0004">Leila Vali</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011709.pub2/information#CD011709-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Rahim Sharafkhani</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/information/en#CD011709-sec-0189">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 October 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011709.pub2">https://doi.org/10.1002/14651858.CD011709.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011709-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011709-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011709-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011709-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011709-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011709-abs-0001" lang="en"> <section id="CD011709-sec-0001"> <h3 class="title" id="CD011709-sec-0001">Background</h3> <p>Schizophrenia is a severe mental disorder with a prevalence of about 1% among the general population. It is listed among the top 10 causes of disability‐adjusted life years (DALYs) worldwide. Antipsychotics are the mainstay treatment. Piperacetazine has been reported to be as clinically effective as chlorpromazine, a well established 'benchmark' antipsychotic, for people with schizophrenia. However, the side effect profiles of these antipsychotics differ and it is important that an evidence base is available comparing the benefits, and potential harms of these two antipsychotics. </p> </section> <section id="CD011709-sec-0002"> <h3 class="title" id="CD011709-sec-0002">Objectives</h3> <p>To assess the clinical and side effects of chlorpromazine for people with schizophrenia and schizophrenia‐like psychoses in comparison with piperacetazine. </p> </section> <section id="CD011709-sec-0003"> <h3 class="title" id="CD011709-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group's Trials Register (6 June 2015 and 8 October 2018) which is based on regular searches of CINAHL, CENTRAL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO and registries of clinical trials. There are no language, date, document type, or publication status limitations for inclusion of records in the register. </p> </section> <section id="CD011709-sec-0004"> <h3 class="title" id="CD011709-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) focusing on chlorpromazine versus piperacetazine for people with schizophrenia, reporting useable data. </p> </section> <section id="CD011709-sec-0005"> <h3 class="title" id="CD011709-sec-0005">Data collection and analysis</h3> <p>We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI), on an intention‐to‐treat basis. For continuous data, we estimated the mean difference (MD) between groups and its 95% CI. We employed a fixed‐effect model for analyses. We assessed risk of bias for included studies and created 'Summary of findings' tables using GRADE. </p> </section> <section id="CD011709-sec-0006"> <h3 class="title" id="CD011709-sec-0006">Main results</h3> <p>We found 12 records referring to six trials. We included five trials, all from the 1970s, randomising 343 participants. We excluded one trial. The overall methodology and data reporting by the trials was poor. Only short‐term data were available. </p> <p>Results from the included trials found that, in terms of global state improvement, when rated by a psychiatrist, there was no clear difference between chlorpromazine and piperacetazine (RR 0.90, 95% CI 0.80 to 1.02; participants = 208; studies = 2; very low‐quality evidence). One trial reported change scores on the mental state scale Brief Psychiatric Rating Scale (BPRS); no clear difference was observed (MD ‐0.40, 95% CI ‐1.41 to 0.61; participants = 182; studies = 1; very low‐quality evidence). Chlorpromazine appears no worse or better than piperacetazine regarding adverse effects. In both treatment groups, around 60% of participants experienced some sort of adverse effect (RR 1.00, 95% CI 0.75 to 1.33; participants = 74; studies = 3; very low‐quality evidence), with approximately 40% of these participants experiencing some parkinsonism‐type movement disorder (RR 0.95, CI 0.61 to 1.49; participants = 106; studies = 3; very low‐quality evidence). No clear difference in numbers of participants leaving the study early for any reason was observed (RR 0.50, 95% CI 0.10 to 2.56; participants = 256; studies = 4; very low‐quality evidence). No trial reported data for change in negative symptoms or economic costs. </p> </section> <section id="CD011709-sec-0007"> <h3 class="title" id="CD011709-sec-0007">Authors' conclusions</h3> <p>The results of this review show chlorpromazine and piperacetazine may have similar clinical efficacy, but data are based on very small numbers of participants and the evidence is very low quality. We can not make firm conclusions based on such data. Currently, should clinicians and people with schizophrenia need to choose between chlorpromazine and piperacetazine they should be aware there is no good quality evidence to base decisions. More high quality research is needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011709-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011709-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011709-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011709-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011709-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011709-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011709-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011709-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011709-abs-0004" lang="en"> <h3>Chlorpromazine versus piperacetazine for schizophrenia</h3> <p><b>Review question</b> </p> <p>Is the antipsychotic drug, chlorpromazine, better or worse than the antipsychotic drug, piperacetazine, for treating the symptoms of schizophrenia? </p> <p><b>Background</b> </p> <p>Schizophrenia is a serious mental illness that severely disrupts a person's thought processes and affects around 1% of the general population. Schizophrenia is listed among the top 10 causes of disability‐adjusted life years (DALYs) worldwide. People with schizophrenia often have a lower life expectancy and an increased risk of suicide. There are two main types of symptoms, positive and negative. Common positive symptoms include delusions (beliefs that are not based in reality) and hallucinations (seeing or hearing things that are not real). Negative symptoms include social withdrawal and lack of motivation and poor emotional response. Positive symptoms are usually of short duration and the negative symptoms can be long term. Schizophrenia is usually treated with a combination of antipsychotic drugs and psychological therapies. Chlorpromazine and piperacetazine are antipsychotic drugs used to treat schizophrenia, however, they both can also cause unpleasant side effects. This review aims to assess evidence from randomised controlled trials regarding the effectiveness and safety of both of these drugs. </p> <p><b>Searching for evidence</b> </p> <p>A search for randomised controlled trials that could be relevant to this review was carried out on 6 June 2015, and another search was carried out 8 October 2018. This was achieved by searching the Specialised Register of Cochrane Schizophrenia. The 2015 search found six possible trials and we carefully checked these to see if we could include them in the review. The 2018 search found no new trials. </p> <p><b>Results</b> </p> <p>Five trials, randomising a total of 343 participants met the review requirements for inclusion. These trials randomly allocated participants to receive either chlorpromazine or piperacetazine. Data were reported for participants' global and mental state after treatment, incidence of adverse effects and numbers leaving the trial early. However, we did not find any data concerning service use, functioning of participants or economic costs of these treatments. The overall results showed chlorpromazine and piperacetazine may have similar clinical efficacy and side effect profiles. However, these results are based on very low‐quality data. </p> <p><b>Conclusions</b> </p> <p>The number of included studies and the sample size of participants included in this review is small, and the quality of data very low, so the results of this review are not conclusive and must be used with caution. Further research would be needed before decisions can be made regarding which drug is more effective. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011709-sec-0176" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011709-sec-0176">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011709-sec-0297">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011709-sec-0176"></div> <h3 class="title" id="CD011709-sec-0177">Implications for practice</h3> <section id="CD011709-sec-0177"> <section id="CD011709-sec-0178"> <h5 class="title">1. For people with schizophrenia</h5> <p>Given a choice between taking chlorpromazine and piperacetazine, there is much more information and evidence concerning the effects of chlorpromazine than for piperacetazine (<a href="#CD011709-tbl-0002">Table 1</a>). People do have idiosyncratic responses to one drug in favour of another. Evidence for a clear average difference between chlorpromazine and piperacetazine is lacking but differences from one person to the next can happen. What limited trial‐based evidence we have suggests piperacetazine is an antipsychotic drug that may have similar effects to chlorpromazine. </p> </section> <section id="CD011709-sec-0179"> <h5 class="title">2. For clinicians</h5> <p>There is no evidence to use piperacetazine before chlorpromazine. All data are poor quality and based on very small, short studies. Should, however, chlorpromazine be impossible to use, and a very similar drug indicated, then piperacetazine could be a viable choice. </p> </section> <section id="CD011709-sec-0180"> <h5 class="title">3. For policy makers</h5> <p>There is no obvious reason from the data we have identified that piperacetazine should not be an available antipsychotic drug. </p> </section> </section> <h3 class="title" id="CD011709-sec-0181">Implications for research</h3> <section id="CD011709-sec-0181"> <section id="CD011709-sec-0182"> <h5 class="title">1. General</h5> <p>We think it important to ensure that all reporting meets the highest <a href="http://www.consort-statement.org/" target="_blank">CONSORT</a> standards and that all data are available for future researchers (<a href="http://www.alltrials.net/" target="_blank">AllTrials</a>). Asking this, retrospectively, of trialists of the 1970s could be seen as overly‐optimistic, but there are examples of studies well before this time which have reported in ways that have fully anticipated standards of the future. Certainly, any future trials relevant to the question focused upon in this review should comply with the highest conduct and reporting standards. The one excluded study asked consent of people to be included but then reported data in such a way as to make them unusable (<a href="./references#CD011709-bbs2-0006" title="SmallS . Piperacetazine (liquid) versus chlorpromazine. Psychopharmacology Bulletin1970;7(1):52‐4. ">Small 1970</a>). This is wasteful and unethical. </p> </section> <section id="CD011709-sec-0183"> <h5 class="title">2. Specific</h5> <section id="CD011709-sec-0184"> <h6 class="title">2.1 Reviews</h6> <p>Sometimes, excluded trials suggest studies that can be included in other existing reviews or generate related questions for new reviews. The search for this review was so specific that we did not identify any trials beyond the direct scope of this review. </p> </section> <section id="CD011709-sec-0185"> <h6 class="title">2.2 Trials</h6> <p>In terms of missing data about the particular question of the comparative effects of these two old drugs, it is not difficult to justify the idea of undertaking another definitive study. If clinicians and patients are using and choosing between the two drugs then there could be an opportunity for good quality evaluation. We realise that such design needs great attention to detail and that there are many calls on research funding and energies ‐ but we have given this question some thought and provide an outline for such a study in <a href="#CD011709-tbl-0003">Table 2</a>. Certainly, studies with much rigorous methodologies, larger sample sizes and with better outcome reporting are needed to explore the role of chlorpromazine and piperacetazine in different patient subgroups. </p> <div class="table" id="CD011709-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Design of a future study</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Methods</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation: randomised (clearly described).<br/> Blinding: single‐blind (outcomes assessor).<br/> Duration: up to 1 year.<br/> Design: parallel. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis: anyone with schizophrenia for whom there is a dilemma of which drugs to</p> <p>use.</p> <p>N = 300.<br/> Age: &gt; 18 years.<br/> Sex: all.<br/> Exclusion criteria: specific contraindication to evaluated treatments. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Chlorpromazine: dose of choice. N = 150.</p> <p>2. Piperacetazine: dose of choice. N = 150.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global state ‐ clinically important change in global state as defined by each study.</p> <p>Mental state ‐ clinically important change in mental state as defined by each study.</p> <p>Mental state ‐ average change in negative symptoms.</p> <p>Adverse events/effects ‐ incidence of serious adverse events/effects.</p> <p>Adverse events/effects ‐ clinically significant extrapyramidal symptoms.</p> <p>Leaving the study early ‐ for any reason.</p> <p>Costs: cost of services, cost of care.</p> <p>Service outcomes: days in hospital, discharged.</p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011709-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011709-sec-0022"></div> <div class="table" id="CD011709-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Chlorpromazine versus piperacetazine for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine versus piperacetazine for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> chlorpromazine versus piperacetazine for schizophrenia (short term) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control<sup>5</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chlorpromazine versus piperacetazine for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: clinically important change</b> ‐ as defined by each of the studies<br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>544 per 1000</b><br/> (208 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> (0.80 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: overall mean change score (BPRS total, high = poor)*</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state change in total scores (BPRS, high = poor) ‐ short term in the intervention groups was<br/> <b>0.40 lower</b><br/> (1.41 lower to 0.61 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* No trial reported clinically important change in mental state which was our predefined outcome of interest </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: specific ‐ clinically important change in negative symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trial reported any data which could be used</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: incidence of adverse effects ‐</b> as defined by each of the studies<br/> Follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>642 per 1000</b><br/> (504 to 828) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> <br/> (0.75 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: clinically important movement disorder (Parkinsonism)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>392 per 1000</b> </p> <p>(252 to 608)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> <br/> (0.61 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early ‐ for any reason</b><br/> Follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><br/> (2 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> <br/> (0.10 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic costs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trial reported relevant data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Serious imprecision: there are very few participants ‐ downgraded by 1.<br/> <sup>2</sup>Strongly suspected publication bias: due to small sample size and insignificant results ‐ downgraded by 1.<br/> <sup>3</sup>Very serious risk of bias: high risk of bias for random sequence generation and allocation concealment. Unclear risk of bias for blinding of outcome assessments and incomplete outcome data ‐ downgraded by 2.<br/> <sup>4</sup>Serious indirectness: not a direct measure of prespecified outcome ‐ downgraded by 1.<br/> <sup>5</sup>All control group rates rounded from control group within the relevant studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011709-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011709-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011709-sec-0197">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011709-sec-0023"></div> <section id="CD011709-sec-0024"> <h3 class="title" id="CD011709-sec-0024">Description of the condition</h3> <p>Schizophrenia is a severe mental disorder with a prevalence of about 1% among the general population. It is listed among the top 10 causes of disability‐adjusted life years (DALYs) worldwide (<a href="./references#CD011709-bbs2-0043" title="RosslerW , SalizeHJ , vanOsJ , Riecher‐RosslerA . Size of burden of schizophrenia and psychotic disorders. European neuropsychopharmacology2005;15(4):399‐409. [PUBMED: 15925493] ">Rossler 2005</a>). People with schizophrenia have a lower life expectancy and an increased risk of suicide (<a href="./references#CD011709-bbs2-0041" title="PalmerBA , PankratzVS , BostwickJM . The lifetime risk of suicide in schizophrenia: a re‐examination. Archives of General Psychiatry2005;62:247‐53. ">Palmer 2005</a>; <a href="./references#CD011709-bbs2-0044" title="SahaS , ChantD , McGrathJ . A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time?. Archives of General Psychiatry2007;64:1123‐31. ">Saha 2007</a>). The illness is characterised by acute positive symptoms, including hallucinations and delusions, and chronic negative symptoms, such as apathy, disorganised thoughts or behaviours, catatonic signs, and lack of motivation (<a href="./references#CD011709-bbs2-0017" title="CarpenterWTJ , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330(10):681‐90. [PUBMED: 8107719] ">Carpenter 1994</a>). Schizophrenia is usually treated with antipsychotics (<a href="./references#CD011709-bbs2-0032" title="KishimotoT , AgarwalV , KishiT , LeuchtS , KaneJM , CorrellCU . Relapse prevention in schizophrenia: a systematic review and meta‐analysis of second‐generation antipsychotics versus first‐generation antipsychotics. Molecular Psychiatry2013;18(1):53‐66. [PUBMED: 22124274] ">Kishimoto 2013</a>). </p> </section> <section id="CD011709-sec-0025"> <h3 class="title" id="CD011709-sec-0025">Description of the intervention</h3> <p>Chlorpromazine is an antipsychotic (class: phenothiazine; subclass: aliphatic side chain; formula: 2‐chloro‐10‐(3‐dimethylaminopropyl) phenothiazine; trade names: many, including Largactil, Hibernal, Megaphen, Solidon, Thorazine; <a href="http://www.who.int/medicines/publications/essentialmedicines/en/" target="_blank">WHO Essential drug</a>; <a href="#CD011709-fig-0001">Figure 1</a>). It is a dopamine antagonist, introduced in the 1950s for the treatment of both acute and chronic psychoses, including schizophrenia and the manic phase of bipolar disorder, as well as amphetamine‐induced psychoses. </p> <div class="figure" id="CD011709-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Chlorpromazine structure" data-id="CD011709-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Chlorpromazine structure</p> </div> </div> </div> <p>Piperacetazine is also an antipsychotic (class: phenothiazine; subclass: piperidine side chain; formula: 10‐[3‐[4‐(2‐hydroxyethyl) piperidino]propyl] phenothiazin‐2‐yl methyl ketone; trade names: Actazine, Quide, Psymod, SC 10.490PC 1421; <a href="#CD011709-fig-0002">Figure 2</a>). It is an antipsychotic drug with purportedly minor extrapyramidal symptoms, but anticholinergic effects of postural hypotension and bradycardia. </p> <div class="figure" id="CD011709-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Piperacetazine structure" data-id="CD011709-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Piperacetazine structure</p> </div> </div> </div> </section> <section id="CD011709-sec-0026"> <h3 class="title" id="CD011709-sec-0026">How the intervention might work</h3> <p>Chlorpromazine works on a variety of receptors in the central nervous system, producing potent anticholinergic, antidopaminergic, antihistaminic, and antiadrenergic effects. Therefore, chlorpromazine causes a variety of side effects, including sedation, constipation, hypotension and extrapyramidal symptoms (<a href="./references#CD011709-bbs2-0033" title="KusumiI , BokuS , TakahashiY . Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis. Psychiatry and Clinical Neurosciences2015;69(5):243‐58. [PUBMED: 25296946] ">Kusumi 2015</a>). </p> <p>Piperacetazine, a phenothiazine of the piperidine class is considered to be a medium‐dosage, high‐potency antipsychotic drug. Piperacetazine has antidopaminergic , anticholinergic, antihistaminic, and antiadrenergic effects. The untoward reactions most frequently associated with the use of piperacetazine are drowsiness, dizziness, weakness, orthostatic hypotension, syncope, and extrapyramidal symptoms. Euphoria, headache, nausea, vomiting, bradycardia, and changes in libido have occurred occasionally. Reactions that occur rarely include dryness of the mouth, nasal stuffiness, galactorrhoea, amenorrhoea, leukopaenia, thrombocytopenia, urinary retention, pedal oedema, convulsions, and jaundice. All of these effects were reversible when the dose was reduced or administration of the drug was discontinued (<a href="./references#CD011709-bbs2-0025" title="GoldsteinSE , BirnbomF . Piperacetazine versus thioridazine in the treatment of organic brain disease: a controlled double‐blind study. Journal of the American Geriatrics Society1976;24(8):355‐8. ">Goldstein 1976</a>; <a href="./references#CD011709-bbs2-0012" title="Anonymous . Evaluation of a new antipsychotic agent. Piperacetazine (quide). JAMA1971;215(5):783‐4. ">Anonymous 1971</a>). </p> </section> <section id="CD011709-sec-0027"> <h3 class="title" id="CD011709-sec-0027">Why it is important to do this review</h3> <p>In an effort to provide the optimal care for people with schizophrenia, careful consideration of the risks and benefits of interventions must be incorporated into a comprehensive treatment plan. Despite the advent of newer antipsychotic drugs considered to be effective for treating the symptoms of schizophrenia with less adverse effects, chlorpromazine is still used commonly and considered a benchmark drug for the treatment of schizophrenia (<a href="./references#CD011709-bbs2-0007" title="AdamsCE , RathboneJ , ThornleyB , ClarkeM , BorrillJ , WahlbeckK , et al. Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Medicine2005;3:15. [PUBMED: 16229742] ">Adams 2005</a>). Therefore, it is important to compare the clinical effectiveness and side effects of chlorpromazine with other antipsychotic drugs. </p> <p>Piperacetazine is a phenothiazine derivative with a piperidine side chain in the position 10 and acetyl radical in the position two. Animal studies have demonstrated that piperacetazine was markedly more potent than chlorpromazine as an antiemetic (prevents vomiting.). Several early studies with newly admitted or chronic psychotic inpatients demonstrated effectiveness of piperacetazine in reducing psychotic symptoms. Side effects reported in these studies were considered mild and were reversible following reduction in dosage or the addition of antiparkinsonian compounds (<a href="./references#CD011709-bbs2-0042" title="RadaRT , DonlonPT . Piperacetazine vs. thioridazine for the control of schizophrenia in outpatients. Psychosomatics1972;13(6):373‐6. [PUBMED: 4153002] ">Rada 1972</a>). </p> <p>To our knowledge, there is no systematic review directly comparing the clinical effects and side effects of chlorpromazine with piperacetazine. This is one of a series of Cochrane Reviews that will build up an overall data set for the effectiveness of chlorpromazine (<a href="#CD011709-tbl-0002">Table 1</a>). </p> <div class="table" id="CD011709-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other Cochrane Reviews in this group</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Review title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acetophenazine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developing protocol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine dose for people with schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0038" title="LiuX , DeHanS . Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007778; CD007778] ">Liu 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cessation of medication for people with schizophrenia already stable on chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0010" title="AlmerieMQ , AlkhateebH , EssaliA , MatarHE , RezkE . Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD006329; CD006329] ">Almerie 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus atypical antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0045" title="SahaKB , SampsonS , ZamanRU . Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD010631; CD010631] ">Saha 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus clotiapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developing protocol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus haloperidol* for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0037" title="LeuchtC , KitzmantelM , ChuaWL , KaneJ , LeuchtS . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2; CD004278] ">Leucht 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus metiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developing protocol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus penfluridol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developing protocol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus piperacetazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0008" title="AdamsCE , AwadGA , RathboneJ , ThornleyB , Soares‐WeiserK . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3; CD000284] ">Adams 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine for psychosis induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0009" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2; CD007445] ">Ahmed 2010</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Since 2015, the title of reviews has been changed to follow the alphabetical order of interventions in the title. </p> </div> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011709-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011709-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011709-sec-0202">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011709-sec-0028"></div> <p>To assess the clinical and side effects of chlorpromazine for people with schizophrenia and schizophrenia‐like psychoses in comparison with piperacetazine. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011709-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011709-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011709-sec-0203">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011709-sec-0029"></div> <section id="CD011709-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011709-sec-0031"> <h4 class="title">Types of studies</h4> <p>All relevant randomised controlled trials (RCTs). If a trial had been described as 'double‐blind' but implied randomisation, we included such trials in a sensitivity analysis (see <a href="#CD011709-sec-0100">Sensitivity analysis</a>). We excluded quasi‐randomised studies, such as those allocating by alternate days of the week. Where people were given additional treatments within chlorpromazine, we only included data if the adjunct treatment was evenly distributed between groups and it was only the chlorpromazine that was randomised. </p> </section> <section id="CD011709-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adults, however defined by individual studies, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, again, by any means of diagnosis. If we found trials where there is a range of related disorders, we only included them if the majority of participants (over 50%) have schizophrenia. If we found trials with adolescent participants, we included them if the majority of participants (over 50%) were over 18 years. </p> <p>We are interested in ensuring that information is relevant to the current care of people with schizophrenia and aimed, where possible, to clearly highlight the current clinical state (acute, early post‐acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD011709-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD011709-sec-0034"> <h5 class="title">1. Chlorpromazine</h5> <p>Any dose or form.</p> </section> <section id="CD011709-sec-0035"> <h5 class="title">2. Piperacetazine</h5> <p>Any dose or form.</p> </section> </section> <section id="CD011709-sec-0036"> <h4 class="title">Types of outcome measures</h4> <p>We divided all outcomes into short‐term (less than 6 months), medium‐term (7 to 12 months) and long‐term (over 12 months) outcomes. </p> <p>We reported binary outcomes recording clear and clinically meaningful degrees of change (e.g. global impression of much improved, or more than 50% improvement on a rating scale ‐ as defined within the trials) before any others. Thereafter, we listed other binary outcomes and then those that are continuous. </p> <section id="CD011709-sec-0037"> <h5 class="title">Primary outcomes</h5> <section id="CD011709-sec-0038"> <h6 class="title">1. Global state ‐ clinically important change.</h6> </section> <section id="CD011709-sec-0039"> <h6 class="title">2. Mental state ‐ overall</h6> <p>2.1 Clinically important change ‐ as defined by each of the studies</p> </section> <section id="CD011709-sec-0040"> <h6 class="title">3. Adverse effects/events</h6> <p>3.1 Incidence of adverse effects ‐ as defined by each of the studies</p> </section> </section> <section id="CD011709-sec-0041"> <h5 class="title">Secondary outcomes</h5> <section id="CD011709-sec-0042"> <h6 class="title">1. Global state</h6> <p>1.1 Any change ‐ as defined by each of the studies<br/> 1.2 Mean endpoint/change score on global state scale </p> </section> <section id="CD011709-sec-0043"> <h6 class="title">2. Mental state</h6> <section id="CD011709-sec-0044"> <p><b>2.1 Overall</b></p> <p>2.1.1 Any change ‐ as defined by each of the studies<br/> 2.2.2 Mean endpoint/change score on mental state scale </p> </section> <section id="CD011709-sec-0045"> <p><b>2.2 Specific</b></p> <p>2.2.1 Clinically important change (e.g. positive, negative, affective symptoms) ‐ as defined by each of the studies<br/> 2.2.2 Any change ‐ as defined by each of the studies<br/> 2.2.3 Mean endpoint or change score on specific mental state scale </p> </section> </section> <section id="CD011709-sec-0046"> <h6 class="title">3. Adverse effects/events</h6> <p><i>3.1 General adverse effects</i> </p> <p>3.1.1 At least one adverse effect<br/> 3.1.2 Mean endpoint or change score on general adverse‐effect scale </p> <p><i>3.2 Specific adverse effects ‐ clinically important</i> </p> <p>3.2.1 Anticholinergic.<br/> 3.2.2 Cardiovascular.<br/> 3.2.3 Central nervous system.<br/> 3.2.4 Gastrointestinal.<br/> 3.2.5 Endocrine (e.g. amenorrhoea, galactorrhoea, hyperlipidaemia, hyperglycaemia, hyperinsulinaemia).<br/> 3.2.6 Haematology (e.g. haemogram, leukopenia, agranulocytosis/neutropenia).<br/> 3.2.7 Hepatitic (e.g. abnormal transaminase, abnormal liver function).<br/> 3.2.8 Metabolic.<br/> 3.2.9 Movement disorders (including extrapyramidal)<br/> 3.2.10 Various other.<br/> 3.2.11 Mean endpoint or change score on specific adverse effect scale </p> <p><i>3.3 Death</i> </p> <p>3.3.1 Any cause except suicide and homicide<br/> 3.3.2 Suicide<br/> 3.3.3 Homicide </p> </section> <section id="CD011709-sec-0047"> <h6 class="title">4. Leaving the study early</h6> <p>4.1 For any reason<br/> 4.2 For specific reason </p> </section> <section id="CD011709-sec-0048"> <h6 class="title">5. Service use</h6> <p>5.1 Hospital admission, readmission, or both<br/> 5.2 Days in hospital </p> </section> <section id="CD011709-sec-0049"> <h6 class="title">6. Quality of life</h6> <p>6.1 Clinically important change ‐ as defined by each of the studies<br/> 7.2 Mean endpoint/change score on quality of life scale </p> </section> <section id="CD011709-sec-0050"> <h6 class="title">8. Satisfaction with care for either recipients of care or carers</h6> <p>8.1 Clinically important change in satisfaction with care ‐ as defined by each of the studies<br/> 8.2 Mean endpoint/change score on satisfaction scale </p> </section> <section id="CD011709-sec-0051"> <h6 class="title">9. Economic outcomes</h6> </section> <section id="CD011709-sec-0052"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD011709-bbs2-0046" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>); and used <a href="http://community.cochrane.org/tools/review-production-tools/gradepro-gdt" target="_blank">GRADEpro GDT</a> to export data from our review to create a 'Summary of findings' table. The 'Summary of findings' table provides outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <p> <ol id="CD011709-list-0001"> <li> <p>Global state ‐ clinically important change ‐ as defined by each of the studies.</p> </li> <li> <p>Mental state: overall ‐ clinically important change ‐ as defined by each of the studies.</p> </li> <li> <p>Mental state: specific ‐ clinically important change in negative symptoms ‐ as defined by each of the studies. </p> </li> <li> <p>Adverse effects/events ‐ general ‐ incidence of adverse effects ‐ as defined by each of the studies </p> </li> <li> <p>Adverse effects/events ‐ clinically important movement disorder‐ as defined by each of the studies. </p> </li> <li> <p>Leaving the study early ‐ for any reason.</p> </li> <li> <p>Economic costs.</p> </li> </ol> </p> <p>If data were not available for these prespecified outcomes, but were available for ones that were similar, we presented the closest outcome to the prespecified one in the table, but took this into account when grading the finding. </p> </section> </section> </section> </section> <section id="CD011709-sec-0053"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011709-sec-0054"> <h4 class="title">Electronic searches</h4> <section id="CD011709-sec-0055"> <h5 class="title">1. Cochrane Schizophrenia Group's Study‐Based Register of Trials</h5> <p>On 6 June 2015 and 8 October 2018, the information specialist searched the register using the following search strategy: </p> <p>(*Chlorpromazine* AND *Piperacetazine*) in Intervention Field of STUDY</p> <p>In such study‐based register, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics (<a href="./references#CD011709-bbs2-0047" title="ShokranehF , AdamsCE . Study‐based registers of randomized controlled trials: Starting a systematic review with data extraction or meta‐analysis. BioImpacts2017;7(4):209‐17. [DOI: 10.15171/bi.2017.25] ">Shokraneh 2017</a>; <a href="./references#CD011709-bbs2-0048" title="ShokranehF , AdamsCE . Gallstone, snake venom and witchcraft for schizophrenia: the challenges of classifying [schizophrenia] trials. Evidence‐Based Medicine2018;23(Suppl. 1):A18. [DOI: 10.1136/bmjebm‐2018‐111024.36] ">Shokraneh 2018</a>). </p> <p>This register is compiled by systematic searches of major resources (AMED, BIOSIS, CENTRAL, CINAHL, ClinicalTrials.Gov, EMBASE, MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their monthly updates, ProQuest Dissertations and Theses A&amp;I and its quarterly update, Chinese databases (CBM, CNKI, and Wanfang) and their annual updates, hand‐searches, grey literature, and conference proceedings (see <a href="http://schizophrenia.cochrane.org/register-trials" target="_blank">Group's website</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> </section> </section> <section id="CD011709-sec-0056"> <h4 class="title">Searching other resources</h4> <section id="CD011709-sec-0057"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all included studies for further relevant studies.</p> </section> <section id="CD011709-sec-0058"> <h5 class="title">2. Personal contact</h5> <p>We contacted the first author of each included study for information regarding unpublished trials. We noted the outcome of this contact in the 'Characteristics of included studies' or 'Characteristics of studies awaiting classification' tables. </p> </section> </section> </section> <section id="CD011709-sec-0059"> <h3 class="title" id="CD011709-sec-0059">Data collection and analysis</h3> <section id="CD011709-sec-0060"> <h4 class="title">Selection of studies</h4> <p>Review authors (MES and LV) independently inspected citations from the searches and identified relevant abstracts. A random 20% sample were independently re‐inspected by RD and RS to ensure reliability. Where disputes arose, the full report was acquired for more detailed scrutiny. Full reports of the abstracts meeting the review criteria were obtained and inspected by MES and LV. Again, a random 20% of reports were re‐inspected by RD and RS in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, we attempted to contact the authors of the study for clarification and when we could not resolve the disagreement, we did not include the trial but placed it in awaiting assessment until a resolution could be made. </p> </section> <section id="CD011709-sec-0061"> <h4 class="title">Data extraction and management</h4> <section id="CD011709-sec-0062"> <h5 class="title">1. Extraction</h5> <p>Review authors LV and RD extracted data from all included studies. In addition, to ensure reliability, RS independently extracted data from a random sample of studies, comprising 10% of the total. Again, any disagreement was discussed, decisions documented and, if necessary, we contacted the authors of studies for clarification. With any remaining problems, MES clarified issues and these final decisions were documented. Data presented only in graphs and figures were extracted whenever possible, but included only if two review authors independently had the same result. We attempted to contact authors through an open‐ended request in order to obtain missing information or for clarification, whenever necessary. If studies were multicentred, where possible, we extracted data relevant to each component centre separately. </p> </section> <section id="CD011709-sec-0063"> <h5 class="title">2. Management</h5> <section id="CD011709-sec-0064"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD011709-sec-0065"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:</p> <p> <ul id="CD011709-list-0002"> <li> <p>the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD011709-bbs2-0039" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); </p> </li> <li> <p>the measuring instrument had not been written or modified by one of the trialists for that particular trial; and </p> </li> <li> <p>the instrument should have been a global assessment of an area of functioning and not subscores which are not, in themselves, validated or shown to be reliable. However, there are exceptions; we would have included subscores from mental state scales measuring positive and negative symptoms of schizophrenia. </p> </li> </ul> </p> <p>Ideally the measuring instrument should either be i) a self‐report or ii) completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; in <a href="#CD011709-sec-0107">Description of studies</a> we noted if this is the case or not. </p> </section> <section id="CD011709-sec-0066"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data: change data can remove a component of between‐person variability from the analysis; however, calculation of change needs two assessments (baseline and endpoint) that can be difficult to obtain in unstable and difficult‐to‐measure conditions, such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. If necessary, we combined endpoint and change data in the analysis, as we preferred to use mean differences (MDs) rather than standardised mean differences (SMDs) throughout (<a href="./references#CD011709-bbs2-0019" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD011709-sec-0067"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to relevant continuous data before inclusion. </p> <p>For endpoint data from studies including fewer than 200 participants.</p> <p> <ol id="CD011709-list-0003"> <li> <p>When a scale starts from the finite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation. If this value was lower than one, it strongly suggests that the data are skewed and we would have excluded these data. If this ratio was higher than one but less than two, there is a suggestion that the data were skewed: we would enter these data and test whether their inclusion or exclusion would change the results substantially. If such data change results, we would have entered as 'other data'. Finally, if the ratio was larger than two we would include these data, because it is less likely that they are skewed (<a href="./references#CD011709-bbs2-0011" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="./references#CD011709-bbs2-0028" title="HigginsJP , DeeksJJ , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> </li> <li> <p>If a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210; <a href="./references#CD011709-bbs2-0031" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), we would modify the calculation described above to take the scale starting point into account. In these cases skewed data are present if 2 standard deviations (SDs) &gt; (S − S min), where S is the mean score and 'S min' is the minimum score. </p> </li> </ol> </p> <p>We would have entered all relevant data from studies of more than 200 participants in the analysis irrespective of the above rules, because skewed data pose less of a problem in large studies. We also entered all relevant change data, as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether or not data are skewed. </p> </section> <section id="CD011709-sec-0068"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we would have converted variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD011709-sec-0069"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, efforts were made to convert outcome measures to dichotomous data. This was done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score, such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD011709-bbs2-0040" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>), or the PANSS (<a href="./references#CD011709-bbs2-0031" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD011709-bbs2-0035" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>; <a href="./references#CD011709-bbs2-0036" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD011709-sec-0070"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for piperacetazine. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not un‐improved'), we reported data where the left of the line indicates an unfavourable outcome. This was noted in the relevant graphs. </p> </section> </section> </section> <section id="CD011709-sec-0071"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Again, review authors MES and LV worked independently to assess risk of bias using criteria described in the <i>Cochrane Handbook for Systemic reviews of Interventions</i> to assess trial quality (<a href="./references#CD011709-bbs2-0029" title="HigginsJP , AltmanDG , SterneJA , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the trial, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>If the raters disagreed, the final rating was made by consensus, with the involvement of another member of the review group (RD). Where inadequate details of randomisation and other characteristics of trials were provided, we contacted trial authors in order to obtain further information. Non‐concurrence in quality assessment was reported, but if disputes arose as to which category a trial was to be allocated, again, we resolved by discussion. </p> <p>We noted the level of risk of bias in both the text of the review and in the 'Summary of findings' table. </p> </section> <section id="CD011709-sec-0072"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011709-sec-0073"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios (ORs) (<a href="./references#CD011709-bbs2-0015" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>), and that OR tend to be interpreted as RR by clinicians (<a href="./references#CD011709-bbs2-0018" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Eight International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The number Needed to treat/harm (NNT/H) statistic with its CIs is intuitively attractive to clinicians, but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD011709-bbs2-0030" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' table, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD011709-sec-0074"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated MD between groups. We preferred not to calculate effect size measures (SMD). However, if scales of very considerable similarity were used, we would have presumed there is a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD011709-sec-0075"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011709-sec-0076"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Authors often fail to account for intraclass correlation in clustered studies, leading to a unit of analysis error whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated (<a href="./references#CD011709-bbs2-0020" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>). This causes type I errors (<a href="./references#CD011709-bbs2-0014" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD011709-bbs2-0026" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>If clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. </p> <p>If clustering was not accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. We would have contacted the first author of studies to obtain intraclass correlation coefficients (ICCs) for their clustered data and adjusted for this by using accepted methods (<a href="./references#CD011709-bbs2-0026" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>We have sought statistical advice and have been advised that the binary data from cluster trials presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC: thus design effect = 1 + (m − 1) * ICC (<a href="./references#CD011709-bbs2-0021" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC is not reported we would have assumed it to be 0.1 (<a href="./references#CD011709-bbs2-0050" title="UkoumunneOC , GullifordMC , ChinnS , SterneJA , BurneyPG . Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed and taken ICCs and relevant data documented in the report into account, synthesis with other studies is possible using the generic inverse variance technique. </p> </section> <section id="CD011709-sec-0077"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a washout phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD011709-bbs2-0023" title="ElbourneD , AltmanDG , HigginsJP , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we would have only used data of the first phase of cross‐over studies. </p> </section> <section id="CD011709-sec-0078"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involves more than two treatment arms, if relevant, we would have presented the additional treatment arms in comparisons. If data are binary, we would simply add these and combine within the 2x2 table. If data are continuous, we would have combined data following the formula in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011709-bbs2-0028" title="HigginsJP , DeeksJJ , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). Where additional treatment arms are not relevant, we would not reproduce these data. </p> </section> </section> <section id="CD011709-sec-0079"> <h4 class="title">Dealing with missing data</h4> <section id="CD011709-sec-0080"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD011709-bbs2-0051" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study are lost, but the total loss is less than 50%, we addressed this within the 'Summary of findings' table by downgrading quality. Finally, we also downgraded quality within the 'Summary of findings' table when loss was 25% to 50% in total. </p> </section> <section id="CD011709-sec-0081"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome is between 0% and 50% and where these data are not clearly described, we would present data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat (ITT) analysis). Those leaving the study early are all assumed to have the same rates of negative outcome as those who completed. We would use the rate of those who stay in the study ‐ in that particular arm of the trial ‐ and apply this also to those who did not. We would have undertaken a sensitivity analysis testing how prone the primary outcomes are to change when data only from people who complete the study to that point are compared to the intention‐to‐treat analysis using the above assumptions. </p> </section> <section id="CD011709-sec-0082"> <h5 class="title">3. Continuous</h5> <section id="CD011709-sec-0083"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome is between 0% and 50%, and data only from people who complete the study to that point are reported, we reproduced these. </p> </section> <section id="CD011709-sec-0084"> <h6 class="title">3.2 Standard deviations</h6> <p>If SDs had not been not reported, we would obtain the missing values from the authors. If these are not available, where there are missing measures of variance for continuous data, but an exact standard error (SE) and CIs are available for group means, and either P value or t value are available for differences in mean, we can calculate SDs according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011709-bbs2-0028" title="HigginsJP , DeeksJJ , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). When only the SE is reported, SDs are calculated by the formula SD = SE * √(n). The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> presents detailed formulae for estimating SDs from P, t or F values, CIs, ranges or other statistics (<a href="./references#CD011709-bbs2-0028" title="HigginsJP , DeeksJJ , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). If these formulae do not apply, we would have calculated the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD011709-bbs2-0024" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome and thus to lose information. Nevertheless, we would have examined the validity of the imputations in a sensitivity analysis that excludes imputed values. </p> </section> <section id="CD011709-sec-0085"> <h6 class="title">3.3 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who left the trials early or were lost to follow‐up. Some trials just present the results of study completers, others use the method of last observation carried forward (LOCF), while more recently methods such as multiple imputation or mixed‐effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem to somewhat better than LOCF (<a href="./references#CD011709-bbs2-0034" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001‐5. [PUBMED: 16905632] ">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We therefore, did not exclude studies based on the statistical approach used. However, we used the more sophisticated approaches, e.g. we would prefer MMRM or multiple‐imputation to LOCF and we would only present completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the item 'incomplete outcome data' of the 'Risk of bias' tool. </p> </section> </section> </section> <section id="CD011709-sec-0086"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD011709-sec-0087"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We inspected all studies for clearly outlying people or situations which we had not predicted would arise. If such situations or participant groups arose, we would fully discuss. </p> </section> <section id="CD011709-sec-0088"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We inspected all studies for clearly outlying methods which we had not predicted would arise. If such methodological outliers arose we would fully discuss. </p> </section> <section id="CD011709-sec-0089"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD011709-sec-0090"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD011709-sec-0091"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> P value. I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD011709-bbs2-0027" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on i) magnitude and direction of effects and ii) strength of evidence for heterogeneity (e.g. P value from Chi<sup>2</sup> test, or a CI for I<sup>2</sup>). We interpreted an I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic, as evidence of substantial levels of heterogeneity (<a href="./references#CD011709-bbs2-0019" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<a href="#CD011709-sec-0096">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD011709-sec-0092"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD011709-bbs2-0022" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD011709-bbs2-0049" title="SterneJA , EggerM , MoherD , editor(s) . Chapter 10: Addressing reporting biases. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). </p> <section id="CD011709-sec-0093"> <h5 class="title">1. Protocol versus full study</h5> <p>We tried to locate protocols of included randomised trials. If the protocol was available, we compared outcomes in the protocol and in the published report . If the protocol was not available, we compared outcomes listed in the methods section of the trial report with actually reported results. </p> </section> <section id="CD011709-sec-0094"> <h5 class="title">2. Funnel plot</h5> <p>We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We would not use funnel plots for outcomes where there are 10 or fewer studies, or where all studies are of similar size. In other cases, where funnel plots are possible, we will seek statistical advice in their interpretation. </p> </section> </section> <section id="CD011709-sec-0095"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies, even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model; it puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose to use the fixed‐effect model for analyses. </p> </section> <section id="CD011709-sec-0096"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD011709-sec-0097"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD011709-sec-0098"> <h6 class="title">1.1 Primary outcomes</h6> <p>We did not anticipate any subgroup analyses.</p> </section> </section> <section id="CD011709-sec-0099"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>We investigated where inconsistency was high. First, we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and removed outlying studies to see if homogeneity was restored. For this review we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present the data. If not, we would not pool data and we would discuss relevant issues. We know of no supporting research for this 10% cut‐off but are investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>When unanticipated clinical or methodological heterogeneity were obvious, we would have stated hypotheses regarding these for future reviews or versions of this review. We did not intend to undertake analyses relating to these. </p> </section> </section> <section id="CD011709-sec-0100"> <h4 class="title">Sensitivity analysis</h4> <section id="CD011709-sec-0101"> <h5 class="title">1. Implication of randomisation</h5> <p>For the primary outcomes, we carried out a sensitivity analysis for a trial that implied randomisation. If adding this trial with implied randomisation study to those with better description of randomisation had made a difference to the result we would not have used data from this trial in the analyses. </p> </section> <section id="CD011709-sec-0102"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD011709-sec-0079">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumption/s and when we used data only from people who completed the study to that point. If there was a substantial difference, we reported results and discussed them, but continued to employ our assumption. </p> <p>Where assumptions were made regarding missing SDs data (see <a href="#CD011709-sec-0079">Dealing with missing data</a>), we would have compared the findings of the primary outcomes when we used our assumption/s and when we used data only from people who completed the study to that point. A sensitivity analysis would have been undertaken to test how prone results are to change when completer‐only data are compared to the imputed data using the above assumption. If there was a substantial difference, we would have reported results and discussed them, but continued to employ our assumption. </p> </section> <section id="CD011709-sec-0103"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (see <a href="#CD011709-sec-0071">Assessment of risk of bias in included studies</a>). If the exclusion of trials at high risk of bias for a domain did not substantially alter the direction of effect or the precision of the effect estimates, then we included the data from these trials in the analyses. </p> </section> <section id="CD011709-sec-0104"> <h5 class="title">4. Imputed values</h5> <p>We would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster‐randomised trials. </p> <p>If substantial differences were noted in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately. </p> </section> <section id="CD011709-sec-0105"> <h5 class="title">5. Fixed‐ and random‐effects models</h5> <p>We synthesised data using a fixed‐effect model, however, we also synthesised data for the primary outcomes using a random‐effects model to evaluate whether this altered the significance of the result. If we found a difference we reported this. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011709-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011709-sec-0106"></div> <section id="CD011709-sec-0107"> <h3 class="title">Description of studies</h3> <p>Please see <a href="./references#CD011709-sec-0195" title="">Characteristics of included studies</a>. </p> <section id="CD011709-sec-0108"> <h4 class="title">Results of the search</h4> <p>See also <a href="#CD011709-fig-0003">Figure 3</a> </p> <div class="figure" id="CD011709-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram for searches, up to 2018" data-id="CD011709-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for searches, up to 2018</p> </div> </div> </div> <p>The searches identified 12 records that referred to six studies. Five of these studies are included in the review and one is excluded. </p> </section> <section id="CD011709-sec-0109"> <h4 class="title">Included studies</h4> <section id="CD011709-sec-0110"> <h5 class="title">1. Methods</h5> <p>All included studies are parallel trials. Four were clearly randomised; <a href="./references#CD011709-bbs2-0005" title="KurlandO . Piperacetazine versus Chlorpromazine‐revision of summary reported on 2/13/70 with additional subjects. Psychopharmacology Bulletin1970;7(1):57‐60. KurlandO . Piperacetazine versus chlorpromazine. Psychopharmacology Bulletin1970;6(4):107‐9. ">Kurland 1970</a> implied randomisation. </p> </section> <section id="CD011709-sec-0111"> <h5 class="title">2. Length of trial</h5> <p>All five were short‐term (under 6 months) trials, with a duration of eight weeks (<a href="./references#CD011709-bbs2-0001" title="GallantDM , BishopMP . Piperacetazine (quide): a controlled evaluation of the elixir in chronic schizophrenic patients. Current Therapeutic Research, Clinical and Experimental1970;12(6):387‐9. GallantDM , BishopMP . Piperacetazine versus chlorpromazine (liquid). Psychopharmacology Bulletin1970;7(1):38‐40. ">Gallant 1970a</a>), or 10 weeks (<a href="./references#CD011709-bbs2-0002" title="GallantDM , BishopMP . Piperacetazine versus chlorpromazine (tablet). Psychopharmacology Bulletin1970;6(4):101‐3. ">Gallant 1970b</a>; <a href="./references#CD011709-bbs2-0003" title="JohnsonAC . Piperacetazine (liquid) versus chlorpromazine. Psychopharmacology Bulletin1970;7(1):55‐7. ">Johnson 1970</a>; <a href="./references#CD011709-bbs2-0005" title="KurlandO . Piperacetazine versus Chlorpromazine‐revision of summary reported on 2/13/70 with additional subjects. Psychopharmacology Bulletin1970;7(1):57‐60. KurlandO . Piperacetazine versus chlorpromazine. Psychopharmacology Bulletin1970;6(4):107‐9. ">Kurland 1970</a>). <a href="./references#CD011709-bbs2-0004" title="JohnsonAC , KulkarniAS . Piperacetazine and chlorpromazine: a comparison. American Journal of Psychiatry1973;130(5):603‐5. KievA , GucluB , KulkarniAS . Evaluation of piperacetazine (quide) injection in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1972;14(7):376‐80. KulkarniAS . Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study. Advances in Biochemical Psychopharmacology1974;9:691‐9. McLaughlinB , KulkarniAS . Comparative evaluation of injectable chlorpromazine and piperacetazine. Psychosomatics1973;14:220‐1. SimeonJ , WadudA , ItilT . A comparison of phenothiazines in managing aggressive episodes in schizophrenic patients. Hospital and Community Psychiatry1975;26(9):574. ">Kulkarni 1972</a> was only 72 hours duration. </p> </section> <section id="CD011709-sec-0112"> <h5 class="title">3. Participants</h5> <p>343 participants were randomised, with all studies stating people entering the trials were people with schizophrenia. The majority of participants were adults over 18 years. <a href="./references#CD011709-bbs2-0004" title="JohnsonAC , KulkarniAS . Piperacetazine and chlorpromazine: a comparison. American Journal of Psychiatry1973;130(5):603‐5. KievA , GucluB , KulkarniAS . Evaluation of piperacetazine (quide) injection in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1972;14(7):376‐80. KulkarniAS . Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study. Advances in Biochemical Psychopharmacology1974;9:691‐9. McLaughlinB , KulkarniAS . Comparative evaluation of injectable chlorpromazine and piperacetazine. Psychosomatics1973;14:220‐1. SimeonJ , WadudA , ItilT . A comparison of phenothiazines in managing aggressive episodes in schizophrenic patients. Hospital and Community Psychiatry1975;26(9):574. ">Kulkarni 1972</a> included a wider age range of 14‐76 years. </p> </section> <section id="CD011709-sec-0113"> <h5 class="title">4. Setting</h5> <p>All studies were conducted in hospital.</p> </section> <section id="CD011709-sec-0114"> <h5 class="title">5. Study size</h5> <p>The mean size of trial was 58, with a range of 16 in <a href="./references#CD011709-bbs2-0002" title="GallantDM , BishopMP . Piperacetazine versus chlorpromazine (tablet). Psychopharmacology Bulletin1970;6(4):101‐3. ">Gallant 1970b</a> to 182 in <a href="./references#CD011709-bbs2-0004" title="JohnsonAC , KulkarniAS . Piperacetazine and chlorpromazine: a comparison. American Journal of Psychiatry1973;130(5):603‐5. KievA , GucluB , KulkarniAS . Evaluation of piperacetazine (quide) injection in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1972;14(7):376‐80. KulkarniAS . Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study. Advances in Biochemical Psychopharmacology1974;9:691‐9. McLaughlinB , KulkarniAS . Comparative evaluation of injectable chlorpromazine and piperacetazine. Psychosomatics1973;14:220‐1. SimeonJ , WadudA , ItilT . A comparison of phenothiazines in managing aggressive episodes in schizophrenic patients. Hospital and Community Psychiatry1975;26(9):574. ">Kulkarni 1972</a>. </p> </section> <section id="CD011709-sec-0115"> <h5 class="title">6. Interventions</h5> <section id="CD011709-sec-0116"> <h6 class="title">6.1 Chlorpromazine</h6> <p>The doses of chlorpromazine in included studies ranged from 30 mg/day in <a href="./references#CD011709-bbs2-0003" title="JohnsonAC . Piperacetazine (liquid) versus chlorpromazine. Psychopharmacology Bulletin1970;7(1):55‐7. ">Johnson 1970</a> to 1350 mg/day in <a href="./references#CD011709-bbs2-0001" title="GallantDM , BishopMP . Piperacetazine (quide): a controlled evaluation of the elixir in chronic schizophrenic patients. Current Therapeutic Research, Clinical and Experimental1970;12(6):387‐9. GallantDM , BishopMP . Piperacetazine versus chlorpromazine (liquid). Psychopharmacology Bulletin1970;7(1):38‐40. ">Gallant 1970a</a>. No study provided details on the mean dose of chlorpromazine. </p> </section> <section id="CD011709-sec-0117"> <h6 class="title">6.2 Piperacetazine</h6> <p>The doses of piperacetazine in included studies ranged from 12 mg/day in <a href="./references#CD011709-bbs2-0005" title="KurlandO . Piperacetazine versus Chlorpromazine‐revision of summary reported on 2/13/70 with additional subjects. Psychopharmacology Bulletin1970;7(1):57‐60. KurlandO . Piperacetazine versus chlorpromazine. Psychopharmacology Bulletin1970;6(4):107‐9. ">Kurland 1970</a> to 800 mg/day in <a href="./references#CD011709-bbs2-0002" title="GallantDM , BishopMP . Piperacetazine versus chlorpromazine (tablet). Psychopharmacology Bulletin1970;6(4):101‐3. ">Gallant 1970b</a>. Again, no study provided details on the mean dose of piperacetazine. </p> </section> </section> <section id="CD011709-sec-0118"> <h5 class="title">7. Outcomes</h5> <p>The following outcomes were reported by the studies: global state, mental state, adverse effects, and leaving the study early. None of the included studies provided evidence on quality of life, levels of satisfaction, service use or cost of care. Most outcomes reported were dichotomous. Two articles reported ordinary outcomes that could be dichotomised (<a href="./references#CD011709-bbs2-0001" title="GallantDM , BishopMP . Piperacetazine (quide): a controlled evaluation of the elixir in chronic schizophrenic patients. Current Therapeutic Research, Clinical and Experimental1970;12(6):387‐9. GallantDM , BishopMP . Piperacetazine versus chlorpromazine (liquid). Psychopharmacology Bulletin1970;7(1):38‐40. ">Gallant 1970a</a>; <a href="./references#CD011709-bbs2-0004" title="JohnsonAC , KulkarniAS . Piperacetazine and chlorpromazine: a comparison. American Journal of Psychiatry1973;130(5):603‐5. KievA , GucluB , KulkarniAS . Evaluation of piperacetazine (quide) injection in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1972;14(7):376‐80. KulkarniAS . Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study. Advances in Biochemical Psychopharmacology1974;9:691‐9. McLaughlinB , KulkarniAS . Comparative evaluation of injectable chlorpromazine and piperacetazine. Psychosomatics1973;14:220‐1. SimeonJ , WadudA , ItilT . A comparison of phenothiazines in managing aggressive episodes in schizophrenic patients. Hospital and Community Psychiatry1975;26(9):574. ">Kulkarni 1972</a>). </p> <p>The following scales provided continuous data for the analysis.</p> <section id="CD011709-sec-0119"> <h6 class="title">7.1 Brief Psychiatric Rating Scale (BPRS)</h6> <p>This scale was developed by Overall and Gorham (<a href="./references#CD011709-bbs2-0040" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>). This rating scale is globally used to measure psychiatric symptoms, such as anxiety, hallucinations, depression and unusual behaviour. </p> </section> <section id="CD011709-sec-0120"> <h6 class="title">7.2 Clinical Global Impression</h6> <p>This rating scale enables clinicians to quantify severity of illness and overall clinical improvement. In this seven‐point scoring system, lower scores indicated decreased severity or better recovery (<a href="./references#CD011709-bbs2-0016" title="BusnerJ , TargumSD . The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont)2007 Jul;4(7):28. ">Busner 2007</a>). </p> </section> <section id="CD011709-sec-0121"> <h6 class="title">7.3 Target Symptom Rating Scale</h6> <p>This is a brief, multi‐informant measure of commonly observed symptoms in child and adolescent clinical work (<a href="./references#CD011709-bbs2-0013" title="BarberCC , NeeseDT , CoyneL , FultzJ , FonagyP . The target symptom rating: A brief clinical measure of acute psychiatric symptoms in children and adolescents. Journal of Clinical Child and Adolescent Psychology 2002 May 1;31(2):181‐92. ">Barber 2002</a>). </p> </section> </section> </section> <section id="CD011709-sec-0122"> <h4 class="title">Excluded studies</h4> <p><a href="./references#CD011709-bbs2-0006" title="SmallS . Piperacetazine (liquid) versus chlorpromazine. Psychopharmacology Bulletin1970;7(1):52‐4. ">Small 1970</a> is the only excluded study. This seems to be an entirely relevant trial but we could not included it as no useable data were reported in the tiny abstract we identified. The style of this abstract is very similar to that of <a href="./references#CD011709-bbs2-0003" title="JohnsonAC . Piperacetazine (liquid) versus chlorpromazine. Psychopharmacology Bulletin1970;7(1):55‐7. ">Johnson 1970</a>, and <a href="./references#CD011709-bbs2-0006" title="SmallS . Piperacetazine (liquid) versus chlorpromazine. Psychopharmacology Bulletin1970;7(1):52‐4. ">Small 1970</a> may well be a further centre involved in one trial, but the <a href="./references#CD011709-bbs2-0003" title="JohnsonAC . Piperacetazine (liquid) versus chlorpromazine. Psychopharmacology Bulletin1970;7(1):55‐7. ">Johnson 1970</a> report does contain some usable data whereas the <a href="./references#CD011709-bbs2-0006" title="SmallS . Piperacetazine (liquid) versus chlorpromazine. Psychopharmacology Bulletin1970;7(1):52‐4. ">Small 1970</a> report does not. </p> <section id="CD011709-sec-0123"> <h5 class="title">Awaiting classification</h5> <p>There are no studies awaiting classification.</p> </section> <section id="CD011709-sec-0124"> <h5 class="title">Ongoing studies</h5> <p>We are unaware of any ongoing studies.</p> </section> </section> </section> <section id="CD011709-sec-0125"> <h3 class="title">Risk of bias in included studies</h3> <p>Please also see <a href="#CD011709-fig-0004">Figure 4</a> and <a href="#CD011709-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD011709-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011709-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011709-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011709-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD011709-sec-0126"> <h4 class="title">Allocation</h4> <p>Four studies have a low risk for selection bias, as they adequately described the methods used for randomisation, reporting that participants were randomised using random numbers. None of the four, however, described how allocation was concealed and we rated them at unclear risk for concealment bias. <a href="./references#CD011709-bbs2-0005" title="KurlandO . Piperacetazine versus Chlorpromazine‐revision of summary reported on 2/13/70 with additional subjects. Psychopharmacology Bulletin1970;7(1):57‐60. KurlandO . Piperacetazine versus chlorpromazine. Psychopharmacology Bulletin1970;6(4):107‐9. ">Kurland 1970</a> used sequential assignment and we rated it at high risk for both allocation and concealment selection bias. </p> </section> <section id="CD011709-sec-0127"> <h4 class="title">Blinding</h4> <p>All included studies were double‐blind and we rated them at low risk for blinding of participants and personnel, apart from <a href="./references#CD011709-bbs2-0004" title="JohnsonAC , KulkarniAS . Piperacetazine and chlorpromazine: a comparison. American Journal of Psychiatry1973;130(5):603‐5. KievA , GucluB , KulkarniAS . Evaluation of piperacetazine (quide) injection in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1972;14(7):376‐80. KulkarniAS . Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study. Advances in Biochemical Psychopharmacology1974;9:691‐9. McLaughlinB , KulkarniAS . Comparative evaluation of injectable chlorpromazine and piperacetazine. Psychosomatics1973;14:220‐1. SimeonJ , WadudA , ItilT . A comparison of phenothiazines in managing aggressive episodes in schizophrenic patients. Hospital and Community Psychiatry1975;26(9):574. ">Kulkarni 1972</a>, which we rated at high risk of bias as it stated that the rating physicians and the nurses were blinded from the identity of the assigned medication. </p> </section> <section id="CD011709-sec-0128"> <h4 class="title">Incomplete outcome data</h4> <p>We rated <a href="./references#CD011709-bbs2-0002" title="GallantDM , BishopMP . Piperacetazine versus chlorpromazine (tablet). Psychopharmacology Bulletin1970;6(4):101‐3. ">Gallant 1970b</a>, <a href="./references#CD011709-bbs2-0003" title="JohnsonAC . Piperacetazine (liquid) versus chlorpromazine. Psychopharmacology Bulletin1970;7(1):55‐7. ">Johnson 1970</a> and <a href="./references#CD011709-bbs2-0004" title="JohnsonAC , KulkarniAS . Piperacetazine and chlorpromazine: a comparison. American Journal of Psychiatry1973;130(5):603‐5. KievA , GucluB , KulkarniAS . Evaluation of piperacetazine (quide) injection in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1972;14(7):376‐80. KulkarniAS . Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study. Advances in Biochemical Psychopharmacology1974;9:691‐9. McLaughlinB , KulkarniAS . Comparative evaluation of injectable chlorpromazine and piperacetazine. Psychosomatics1973;14:220‐1. SimeonJ , WadudA , ItilT . A comparison of phenothiazines in managing aggressive episodes in schizophrenic patients. Hospital and Community Psychiatry1975;26(9):574. ">Kulkarni 1972</a> at low risk of bias for incomplete outcome data because there was either no attrition, or attrition was reported. We rated the other studies at unclear risk for this item as information regarding missing values or attrition was not provided (<a href="./references#CD011709-bbs2-0001" title="GallantDM , BishopMP . Piperacetazine (quide): a controlled evaluation of the elixir in chronic schizophrenic patients. Current Therapeutic Research, Clinical and Experimental1970;12(6):387‐9. GallantDM , BishopMP . Piperacetazine versus chlorpromazine (liquid). Psychopharmacology Bulletin1970;7(1):38‐40. ">Gallant 1970a</a>; <a href="./references#CD011709-bbs2-0005" title="KurlandO . Piperacetazine versus Chlorpromazine‐revision of summary reported on 2/13/70 with additional subjects. Psychopharmacology Bulletin1970;7(1):57‐60. KurlandO . Piperacetazine versus chlorpromazine. Psychopharmacology Bulletin1970;6(4):107‐9. ">Kurland 1970</a>). </p> </section> <section id="CD011709-sec-0129"> <h4 class="title">Selective reporting</h4> <p>Only two studies reported all prestated outcomes and had a 'low' risk of reporting bias (<a href="./references#CD011709-bbs2-0004" title="JohnsonAC , KulkarniAS . Piperacetazine and chlorpromazine: a comparison. American Journal of Psychiatry1973;130(5):603‐5. KievA , GucluB , KulkarniAS . Evaluation of piperacetazine (quide) injection in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1972;14(7):376‐80. KulkarniAS . Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study. Advances in Biochemical Psychopharmacology1974;9:691‐9. McLaughlinB , KulkarniAS . Comparative evaluation of injectable chlorpromazine and piperacetazine. Psychosomatics1973;14:220‐1. SimeonJ , WadudA , ItilT . A comparison of phenothiazines in managing aggressive episodes in schizophrenic patients. Hospital and Community Psychiatry1975;26(9):574. ">Kulkarni 1972</a>; <a href="./references#CD011709-bbs2-0005" title="KurlandO . Piperacetazine versus Chlorpromazine‐revision of summary reported on 2/13/70 with additional subjects. Psychopharmacology Bulletin1970;7(1):57‐60. KurlandO . Piperacetazine versus chlorpromazine. Psychopharmacology Bulletin1970;6(4):107‐9. ">Kurland 1970</a>). The others were at unclear risk for selective reporting as no information regarding prespecified outcomes was provided. </p> </section> <section id="CD011709-sec-0130"> <h4 class="title">Other potential sources of bias</h4> <p>Only one study reported its source of funding (<a href="./references#CD011709-bbs2-0001" title="GallantDM , BishopMP . Piperacetazine (quide): a controlled evaluation of the elixir in chronic schizophrenic patients. Current Therapeutic Research, Clinical and Experimental1970;12(6):387‐9. GallantDM , BishopMP . Piperacetazine versus chlorpromazine (liquid). Psychopharmacology Bulletin1970;7(1):38‐40. ">Gallant 1970a</a>). In this study, the drugs were partly supplied by a pharmaceutical company and we rated this at low risk of bias. The other studies did not report on funding and we assigned these trials an unclear risk of bias for this domain. </p> </section> </section> <section id="CD011709-sec-0131"> <h3 class="title" id="CD011709-sec-0131">Effects of interventions</h3> <p>See: <a href="./full#CD011709-tbl-0001"><b>Summary of findings for the main comparison</b> Chlorpromazine versus piperacetazine for schizophrenia</a> </p> <section id="CD011709-sec-0132"> <h4 class="title">1. Chlorpromazine versus piperacetazine (short term)</h4> <section id="CD011709-sec-0133"> <h5 class="title">1.1 Global state: 1. Clinically important change (psychiatrist‐rated)</h5> <p>Two studies involving 208 participants reported clinically important change in global state. There was not a clear difference between chlorpromazine and piperacetazine. For this outcome heterogeneity is high (risk ratio (RR) 0.90, 95% confidence interval (CI) 0.80 to 1.02; participants = 208; studies = 2; I<sup>2</sup> = 71%; very low‐quality evidence; <a href="./references#CD011709-fig-0006" title="">Analysis 1.1</a>). </p> </section> <section id="CD011709-sec-0134"> <h5 class="title">1.2 Global state: 2a. Any change (improvement after first injection)</h5> <p>One study with 182 participants reported numbers improved after an initial injection of the treatment drug for 26 participants. There was not a clear difference between chlorpromazine and piperacetazine (RR 1.00, 95% CI 0.87 to 1.15; participants = 26; studies = 1; <a href="./references#CD011709-fig-0007" title="">Analysis 1.2</a>). </p> </section> <section id="CD011709-sec-0135"> <h5 class="title">1.3 Global state: 2b. Any change (improved) (CGI, high = poor)</h5> <p>There was not a clear difference between chlorpromazine and piperacetazine for global state improvement using the CGI (RR 0.89, 95% CI 0.80 to 1.01; participants = 182; studies = 1; <a href="./references#CD011709-fig-0008" title="">Analysis 1.3</a>) </p> </section> <section id="CD011709-sec-0136"> <h5 class="title">1.4 Mental state: 1a. Overall: mean change score (BPRS total, high = poor)</h5> <p>There was no clear difference between chlorpromazine and piperacetazine for mental state when measured using BPRS total change scores (mean difference (MD) ‐0.40, 95% CI ‐1.41 to 0.61; participants = 182; studies = 1, very low‐quality evidence; <a href="./references#CD011709-fig-0009" title="">Analysis 1.4</a>). </p> </section> <section id="CD011709-sec-0137"> <h5 class="title">1.5 Mental state: 1b. Overall: mean change score (TSRS total, high = poor)</h5> <p>There was no clear difference between chlorpromazine and piperacetazine for mental state when measured using TSRS total change scores (MD 0.60, 95% CI ‐1.06 to 2.26; participants = 182; studies = 1; <a href="./references#CD011709-fig-0010" title="">Analysis 1.5</a>). </p> </section> <section id="CD011709-sec-0138"> <h5 class="title">1.6 Adverse effects/events: 1. General: incidence of adverse effects</h5> <p>Incidence of adverse effects did not differ between treatment groups (RR 1.00, 95% CI 0.75 to 1.33; participants = 74; studies = 3; very low‐quality evidence; <a href="./references#CD011709-fig-0011" title="">Analysis 1.6</a>). </p> </section> <section id="CD011709-sec-0139"> <h5 class="title">1.7 Adverse effects/events: 2a. Specific: cardiovascular</h5> <section id="CD011709-sec-0140"> <h6 class="title">1.7.1 Blood pressure, dizziness, syncope, tachycardia</h6> <p>Incidence of cardiac adverse effects did not differ between treatment groups. There was high heterogeneity for this outcome (RR 0.74, 95% CI 0.47 to 1.16; participants = 208; studies = 2; I<sup>2</sup> = 80%; <a href="./references#CD011709-fig-0012" title="">Analysis 1.7</a>) </p> </section> </section> <section id="CD011709-sec-0141"> <h5 class="title">1.8 Adverse effects/events: 2b. Specific: central nervous system</h5> <p>Two studies reported on various cental nervous system adverse effects (<a href="./references#CD011709-fig-0013" title="">Analysis 1.8</a>). </p> <section id="CD011709-sec-0142"> <h6 class="title">1.8.1 Dry mouth</h6> <p>Number of participants experiencing 'dry mouth' was similar between the chlorpromazine and piperacetazine groups (RR 4.89, 95% CI 0.24 to 100.51; participants = 182; studies = 1). </p> </section> <section id="CD011709-sec-0143"> <h6 class="title">1.8.2 Headache</h6> <p>Number of participants experiencing headache was similar between the chlorpromazine and piperacetazine groups (RR 0.33, 95% CI 0.01 to 7.90; participants = 182; studies = 1). </p> </section> <section id="CD011709-sec-0144"> <h6 class="title">1.8.3 Nausea/vomiting</h6> <p>Number of participants experiencing nausea/vomiting was similar between the chlorpromazine and piperacetazine groups (RR 1.54, 95% CI 0.42 to 5.73; participants = 208; studies = 2). </p> </section> <section id="CD011709-sec-0145"> <h6 class="title">1.8.4 Sleepiness</h6> <p>There was a clear difference in the number of participants experiencing sleepiness in the chlorpromazine group compared to the piperacetazine group. Fewer participants experienced this adverse effect in the piperacetazine group (RR 2.87, 95% CI 1.13 to 7.31; participants = 208; studies = 2). </p> </section> <section id="CD011709-sec-0146"> <h6 class="title">1.8.5 Weakness</h6> <p>Number of participants experiencing weakness was similar between the chlorpromazine and piperacetazine groups (RR 0.82, 95% CI 0.23 to 2.95; participants = 182; studies = 1). </p> </section> </section> <section id="CD011709-sec-0147"> <h5 class="title">1.9 Adverse effects/events: 2c. Specific: hepatitic</h5> <p>One study reported on hepatic adverse effects (<a href="./references#CD011709-fig-0014" title="">Analysis 1.9</a>). </p> <section id="CD011709-sec-0148"> <h6 class="title">1.9.1 Liver problems (changes in alkaline phosphatase and SGPT levels)</h6> <p>Number of participants experiencing changes in alkaline phosphatase and SGPT was similar between the chlorpromazine and piperacetazine groups (RR 1.00, 95% CI 0.16 to 6.07; participants = 26; studies = 1). </p> </section> </section> <section id="CD011709-sec-0149"> <h5 class="title">1.10 Adverse effects/events: 2d. Specific: movement disorders</h5> <p>Four studies reported on various movement disorders (<a href="./references#CD011709-fig-0015" title="">Analysis 1.10</a>). </p> <section id="CD011709-sec-0150"> <h6 class="title">1.10.1 Akathisia</h6> <p>The number of participants experiencing akathisia was similar between the chlorpromazine and piperacetazine groups (RR 0.59, 95% CI 0.08 to 4.36; participants = 208; studies = 2). </p> </section> <section id="CD011709-sec-0151"> <h6 class="title">1.10.2 Dystonia</h6> <p>The number of participants experiencing dystonia was similar between the chlorpromazine and piperacetazine groups (RR 1.96, 95% CI 0.18 to 21.20; participants = 182; studies = 1). </p> </section> <section id="CD011709-sec-0152"> <h6 class="title">1.10.3 Parkinsonism</h6> <p>The number of participants experiencing parkinsonism effects was similar between the chlorpromazine and piperacetazine groups (RR 0.95, 95% CI 0.61 to 1.49; participants = 106; studies = 3; very low‐quality evidence). </p> </section> <section id="CD011709-sec-0153"> <h6 class="title">1.10.4 Rigidity</h6> <p>The number of participants experiencing rigidity was similar between the chlorpromazine and piperacetazine groups (RR 1.01, 95% CI 0.15 to 7.00; participants = 208; studies = 2). </p> </section> <section id="CD011709-sec-0154"> <h6 class="title">1.10.5 Tremor</h6> <p>The number of participants experiencing tremor was similar between the chlorpromazine and piperacetazine groups (RR 1.02, 95% CI 0.15 to 7.10; participants = 182; studies = 1). </p> </section> </section> <section id="CD011709-sec-0155"> <h5 class="title">1.11 Leaving the study early</h5> <p>Three trials reported participants leaving the study early (<a href="./references#CD011709-fig-0016" title="">Analysis 1.11</a>). </p> <section id="CD011709-sec-0156"> <h6 class="title">1.11.1 For any reason</h6> <p>There was no clear difference in number of participants leaving the study early for any reason (RR 0.50, 95% CI 0.10 to 2.56; participants = 256; studies = 4; very low‐quality evidence). </p> </section> <section id="CD011709-sec-0157"> <h6 class="title">1.12 Due to adverse effects</h6> <p>There was no clear difference in number of participants leaving the study early because of adverse effects (RR 0.98, 95% CI 0.06 to 15.40; participants = 182; studies = 1). </p> </section> </section> <section id="CD011709-sec-0158"> <h5 class="title">Missing outcomes</h5> <p>No data were reported for service use, economic outcomes or quality of life.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011709-sec-0159" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011709-sec-0159">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011709-sec-0280">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011709-sec-0159"></div> <section id="CD011709-sec-0160"> <h3 class="title" id="CD011709-sec-0160">Summary of main results</h3> <p>The summary below indicates the outcomes selected for <a href="./full#CD011709-tbl-0001">summary of findings Table for the main comparison</a> and highlights the other findings of this review for evidence‐based decision making. </p> <section id="CD011709-sec-0161"> <h4 class="title">1. Global state: clinically important change</h4> <p>Very low‐quality evidence from two studies suggested no real difference between chlorpromazine and piperacetazine for this global effect. The studies are heterogenous for this outcome (71%) but we could not found any source for it. This would fit logically since these drugs are both from the phenothiazines family. </p> </section> <section id="CD011709-sec-0162"> <h4 class="title">2. Mental state</h4> <section id="CD011709-sec-0163"> <h5 class="title">2.1 Overall and specific: Clinically important change/changes in the mean total scores</h5> <p>Our findings indicated no clear difference between chlorpromazine and piperacetazine according to Brief Psychiatric Rating Scale (BPRS) scores. We, however, prestated that a binary outcome was desirable. The studies did not report such an outcome. This could be a function of trial design. Fine‐grain measures are often desired over more clinically interpretable outcomes. In this case continuous data seem to indicate that there is no difference between groups. There should be clear binary outcomes but, if not available we have to settle for continuous findings as second best. As for the global state outcome, mental state findings do not indicate a difference between the two drugs. </p> </section> <section id="CD011709-sec-0164"> <h5 class="title">2.2 Missing data for negative symptoms</h5> <p>We did not identify relevant data for negative symptoms. All trials are old. The more focused approach to categorisation of symptoms into positive and negative groups is predated by all studies. Sometimes old data are so well reported that we use them in a way as to present effects on symptoms that might now be categorised as 'negative' ‐ but this was not the case for these trials. </p> </section> </section> <section id="CD011709-sec-0165"> <h4 class="title">3. Adverse effects</h4> <section id="CD011709-sec-0166"> <h5 class="title">3.1 General</h5> <p>The total number of people experiencing some sort of adverse effect is about 66% in both groups ‐ with no difference between the drugs. When it comes to specific effects, piperacetazine produced higher rates of sleepiness in people with schizophrenia than chlorpromazine. </p> </section> <section id="CD011709-sec-0167"> <h5 class="title">3.2 Specific: movement disorders</h5> <p>We did identify data for 'parkinsonism'; there was no difference between the two groups in data derived from three studies. Although these data are heterogenous for this outcome (80%) without specific sources and very low quality for the reasons outlined in <a href="./full#CD011709-tbl-0001">summary of findings Table for the main comparison</a> they are, nevertheless, the best available. There is no difference between the more unfamiliar piperacetazine and chlorpromazine but around 40% of both groups experienced this disfiguring and disabling adverse effect. The doses of medication in these old studies was, perhaps, for some of the trials, high and modern treatment would probably avoid such doses ‐ especially those in <a href="./references#CD011709-bbs2-0001" title="GallantDM , BishopMP . Piperacetazine (quide): a controlled evaluation of the elixir in chronic schizophrenic patients. Current Therapeutic Research, Clinical and Experimental1970;12(6):387‐9. GallantDM , BishopMP . Piperacetazine versus chlorpromazine (liquid). Psychopharmacology Bulletin1970;7(1):38‐40. ">Gallant 1970a</a> and <a href="./references#CD011709-bbs2-0002" title="GallantDM , BishopMP . Piperacetazine versus chlorpromazine (tablet). Psychopharmacology Bulletin1970;6(4):101‐3. ">Gallant 1970b</a> ‐ but parkinsonism is an important and off‐putting adverse effect. </p> </section> </section> <section id="CD011709-sec-0168"> <h4 class="title">4. Leaving the study early</h4> <p>Four studies reported data with no difference between groups (<a href="./references#CD011709-fig-0016" title="">Analysis 1.11</a>). We had to rate these data as being of very low‐quality but, again, they are the best we are likely to find. However, just over 1% left each group. These are very low rates indeed. It could be a testimony to good trial design, a compliant participant group or limited opportunities to leave studies. We are not sure which, if any is important. We do not really believe this reflects the situation that would happen in the 'real world'. </p> </section> <section id="CD011709-sec-0169"> <h4 class="title">5. Economic costs</h4> <p>It is not really surprising that no data are available and we may have been overly hopeful to stipulate it as one of our 'Summary of findings' outcomes ‐ nevertheless it remains important. Proxy outcomes such as relapse and time in hospital can be used in place of direct cost data ‐ but we also lack these data for this particular comparison. </p> </section> </section> <section id="CD011709-sec-0170"> <h3 class="title" id="CD011709-sec-0170">Overall completeness and applicability of evidence</h3> <section id="CD011709-sec-0171"> <h4 class="title">1. Completeness</h4> <p>Of the five studies included, only two reported data for the primary outcomes of global state and mental state. Studies reported other useful effects but evidence on all outcomes is incomplete. There were no data available for behaviour, service use, relapse, level of satisfaction and cost of care. </p> </section> <section id="CD011709-sec-0172"> <h4 class="title">2. Applicability</h4> <p>All included studies were from the 1970s, which could lead to issues of applicability. No study reported their diagnostic criteria and the definition of schizophrenia has evolved during this period. It is difficult to know how this effects applicability. The people within the trials were recognisable by descriptions given within the trials and may not be that different to people with the illness today. </p> <p>Doses of drugs were also reasonably recognisable by today's standards ‐ although the two Gallant studies did have high maximums (<a href="./references#CD011709-bbs2-0001" title="GallantDM , BishopMP . Piperacetazine (quide): a controlled evaluation of the elixir in chronic schizophrenic patients. Current Therapeutic Research, Clinical and Experimental1970;12(6):387‐9. GallantDM , BishopMP . Piperacetazine versus chlorpromazine (liquid). Psychopharmacology Bulletin1970;7(1):38‐40. ">Gallant 1970a</a>; <a href="./references#CD011709-bbs2-0002" title="GallantDM , BishopMP . Piperacetazine versus chlorpromazine (tablet). Psychopharmacology Bulletin1970;6(4):101‐3. ">Gallant 1970b</a>). </p> <p>Although data from these trials is nearly half a century old ‐ we do not feel they are entirely inapplicable to today's practice. </p> </section> </section> <section id="CD011709-sec-0173"> <h3 class="title" id="CD011709-sec-0173">Quality of the evidence</h3> <p>The quality of evidence, based on GRADE is very low. Four studies reported the methods of random sequence generation but only one of these reported methods of allocation concealment. One study implied randomisation and was at high risk of bias for random sequence generation. Two studies had unclear risk of bias for blinding assessments and incomplete outcome data. Only one study stated that physicians and rating nurses were blinded to the treatments. For the one study that reported its source of funding, we rated it at low risk of bias overall (<a href="./references#CD011709-bbs2-0001" title="GallantDM , BishopMP . Piperacetazine (quide): a controlled evaluation of the elixir in chronic schizophrenic patients. Current Therapeutic Research, Clinical and Experimental1970;12(6):387‐9. GallantDM , BishopMP . Piperacetazine versus chlorpromazine (liquid). Psychopharmacology Bulletin1970;7(1):38‐40. ">Gallant 1970a</a>). The other studies did not report on funding at all and, taking others issues into account, we had to assign these trials as being of 'unclear' risk of bias. Studies often reported no usable data on important outcomes as they solely reported statistical measures of probability (P value) or means without any standard deviation or standard error. We also detected imprecision and publication bias for three included studies, leading to very low‐quality in <a href="./full#CD011709-tbl-0001">summary of findings Table for the main comparison</a> table. </p> <p>We realise we are judging trials of the far past by standards of today. The trials in this review are imperfect but important and pioneering. They partially tell a story of evaluation of a now old and largely unused drug. At least these trials took place. Many treatments practiced in modern mental health care have no trials at all to support their use. </p> </section> <section id="CD011709-sec-0174"> <h3 class="title" id="CD011709-sec-0174">Potential biases in the review process</h3> <p>For this review, the search was based on Cochrane Schizophrenia's Trials Register. We are unaware of any other unpublished trials related to this review. We had limited reports of a few small trials. Publication bias and reporting bias could well be an issue in what we have done. We have no reason to skew results in favour of either compound. We have no reason to believe that searches for this review are any more prone to biases than other reviews. </p> </section> <section id="CD011709-sec-0175"> <h3 class="title" id="CD011709-sec-0175">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of any other systematic reviews on the efficacy of chlorpromazine versus piperacetazine for schizophrenia. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011709-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Chlorpromazine structure" data-id="CD011709-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Chlorpromazine structure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Piperacetazine structure" data-id="CD011709-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Piperacetazine structure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for searches, up to 2018" data-id="CD011709-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram for searches, up to 2018</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011709-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011709-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 1 Global state: 1. Clinically important change (psychiatrist‐rated)." data-id="CD011709-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 1 Global state: 1. Clinically important change (psychiatrist‐rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 2 Global state: 2a. Any change (improvement after first injection)." data-id="CD011709-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 2 Global state: 2a. Any change (improvement after first injection). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 3 Global state: 2b. Any change (improved) (CGI, high = poor)." data-id="CD011709-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 3 Global state: 2b. Any change (improved) (CGI, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 4 Mental state: 1a. Overall: mean change score (BPRS total, high = poor )." data-id="CD011709-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 4 Mental state: 1a. Overall: mean change score (BPRS total, high = poor ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 5 Mental state: 1b. Overall: mean change score (TSRS total, high = poor)." data-id="CD011709-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 5 Mental state: 1b. Overall: mean change score (TSRS total, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 6 Adverse effects/events: 1. General: incidence of adverse effects." data-id="CD011709-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 6 Adverse effects/events: 1. General: incidence of adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 7 Adverse effects/events: 2a. Specific: cardiovascular." data-id="CD011709-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 7 Adverse effects/events: 2a. Specific: cardiovascular. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 8 Adverse effects/events: 2b. Specific: central nervous system." data-id="CD011709-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 8 Adverse effects/events: 2b. Specific: central nervous system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 9 Adverse effects/events: 2c. Specific: hepatitic." data-id="CD011709-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 9 Adverse effects/events: 2c. Specific: hepatitic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 10 Adverse effects/events: 2d. Specific: movement disorders." data-id="CD011709-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 10 Adverse effects/events: 2d. Specific: movement disorders. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011709-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/urn:x-wiley:14651858:media:CD011709:CD011709-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_t/tCD011709-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 11 Leaving the study early." data-id="CD011709-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus piperacetazine (short term), Outcome 11 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/media/CDSR/CD011709/image_n/nCD011709-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD011709-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Design of a future study</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Methods</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation: randomised (clearly described).<br/> Blinding: single‐blind (outcomes assessor).<br/> Duration: up to 1 year.<br/> Design: parallel. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis: anyone with schizophrenia for whom there is a dilemma of which drugs to</p> <p>use.</p> <p>N = 300.<br/> Age: &gt; 18 years.<br/> Sex: all.<br/> Exclusion criteria: specific contraindication to evaluated treatments. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Chlorpromazine: dose of choice. N = 150.</p> <p>2. Piperacetazine: dose of choice. N = 150.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global state ‐ clinically important change in global state as defined by each study.</p> <p>Mental state ‐ clinically important change in mental state as defined by each study.</p> <p>Mental state ‐ average change in negative symptoms.</p> <p>Adverse events/effects ‐ incidence of serious adverse events/effects.</p> <p>Adverse events/effects ‐ clinically significant extrapyramidal symptoms.</p> <p>Leaving the study early ‐ for any reason.</p> <p>Costs: cost of services, cost of care.</p> <p>Service outcomes: days in hospital, discharged.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Design of a future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011709-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Chlorpromazine versus piperacetazine for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine versus piperacetazine for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> chlorpromazine versus piperacetazine for schizophrenia (short term) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control<sup>5</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chlorpromazine versus piperacetazine for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: clinically important change</b> ‐ as defined by each of the studies<br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>544 per 1000</b><br/> (208 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> (0.80 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: overall mean change score (BPRS total, high = poor)*</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state change in total scores (BPRS, high = poor) ‐ short term in the intervention groups was<br/> <b>0.40 lower</b><br/> (1.41 lower to 0.61 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* No trial reported clinically important change in mental state which was our predefined outcome of interest </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: specific ‐ clinically important change in negative symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trial reported any data which could be used</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: incidence of adverse effects ‐</b> as defined by each of the studies<br/> Follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>642 per 1000</b><br/> (504 to 828) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> <br/> (0.75 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: clinically important movement disorder (Parkinsonism)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>392 per 1000</b> </p> <p>(252 to 608)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> <br/> (0.61 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early ‐ for any reason</b><br/> Follow‐up: mean 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><br/> (2 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> <br/> (0.10 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic costs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trial reported relevant data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Serious imprecision: there are very few participants ‐ downgraded by 1.<br/> <sup>2</sup>Strongly suspected publication bias: due to small sample size and insignificant results ‐ downgraded by 1.<br/> <sup>3</sup>Very serious risk of bias: high risk of bias for random sequence generation and allocation concealment. Unclear risk of bias for blinding of outcome assessments and incomplete outcome data ‐ downgraded by 2.<br/> <sup>4</sup>Serious indirectness: not a direct measure of prespecified outcome ‐ downgraded by 1.<br/> <sup>5</sup>All control group rates rounded from control group within the relevant studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Chlorpromazine versus piperacetazine for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011709-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other Cochrane Reviews in this group</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Review title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acetophenazine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developing protocol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine dose for people with schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0038" title="LiuX , DeHanS . Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007778; CD007778] ">Liu 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cessation of medication for people with schizophrenia already stable on chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0010" title="AlmerieMQ , AlkhateebH , EssaliA , MatarHE , RezkE . Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD006329; CD006329] ">Almerie 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus atypical antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0045" title="SahaKB , SampsonS , ZamanRU . Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD010631; CD010631] ">Saha 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus clotiapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developing protocol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus haloperidol* for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0037" title="LeuchtC , KitzmantelM , ChuaWL , KaneJ , LeuchtS . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2; CD004278] ">Leucht 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus metiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developing protocol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus penfluridol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Developing protocol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus piperacetazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0008" title="AdamsCE , AwadGA , RathboneJ , ThornleyB , Soares‐WeiserK . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3; CD000284] ">Adams 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine for psychosis induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011709-bbs2-0009" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2; CD007445] ">Ahmed 2010</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>*Since 2015, the title of reviews has been changed to follow the alphabetical order of interventions in the title. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other Cochrane Reviews in this group</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/full#CD011709-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011709-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Chlorpromazine versus piperacetazine (short term)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. Clinically important change (psychiatrist‐rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.80, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.80, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2a. Any change (improvement after first injection) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.87, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 2b. Any change (improved) (CGI, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.80, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1a. Overall: mean change score (BPRS total, high = poor ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.41, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1b. Overall: mean change score (TSRS total, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐1.06, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects/events: 1. General: incidence of adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.75, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects/events: 2a. Specific: cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.47, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Blood pressure, dizziness, syncope, tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.47, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects/events: 2b. Specific: central nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.89 [0.24, 100.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.42, 5.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Sleepiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [1.13, 7.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.23, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects/events: 2c. Specific: hepatitic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Liver problems (changes in alkaline phosphatase and SGPT levels)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.16, 6.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects/events: 2d. Specific: movement disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.08, 4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.18, 21.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.61, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Rigidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.15, 7.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.15, 7.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 For any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.10, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Due to adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.40]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Chlorpromazine versus piperacetazine (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011709.pub2/references#CD011709-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011709.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011709-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011709-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011709-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011709-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011709-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011709-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011709\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011709\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011709\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011709\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011709\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011709.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011709.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011709.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011709.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011709.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719821654"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011709.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719821657"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011709.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df21fc96a937f',t:'MTc0MDcxOTgyMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 